Liquidia Will Continue To Advance YUTREPIA And L606 Clinical Programs As Previously Outlined; Liquidia Has Submitted A Supplement To Remove The PH-ILD Indication From YUTREPIA’ ’s Label And No Longer Promotes It For PH-ILD
The settlement follows the September 30, 2026, ruling by the U.S. District Court for the District of Delaware (the Court) that claims 1 and 14 of U.S. Patent No. 11,826,327 (the ’327 patent) are valid and infringed by
Liquidia is removing one approved use from its YUTREPIA medicine due to a legal ruling. The company will keep working on YUTREPIA and another drug called L606 as planned.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.